Fox News Charlotte: The Use of AI in Drug-making
Fox News Charlotte features Christian Olsen, Vice President of Biologics at Dotmatics, discussing how AI, particularly through the Dotmatics Luma platform, is revolutionizing pharmaceutical drug discovery by reducing costs and accelerating time to market while addressing complex research challenges in laboratories.
In this Fox News Charlotte feature, Christian Olsen, Dotmatics' Vice President of Biologics, discusses the transformative role of artificial intelligence (AI) in advancing scientific research and pharmaceutical drug discovery. The conversation emphasizes how AI can reduce the cost and time to market for new drugs. Dotmatics Luma is highlighted as a platform that leverages AI to provide innovative solutions to complex research challenges faced by laboratories today.
The feature explores how the Luma scientific intelligence platform is playing a pivotal role in shaping the future of scientific discovery.
Related
3 Customer Trends We’re Watching in 2025
In 2025, life science teams are prioritizing three key trends—Lab-in-a-Loop platforms that integrate instruments, data, workflows, and models to boost R&D efficiency; true multimodal discovery enabled by flexible informatics supporting diverse data types without fragmented tools; and Composite AI leveraging layered, governed, and traceable data across disciplines—all aimed at delivering tangible scientific innovation while addressing resource constraints and stringent AI governance requirements.
Data Evolution in Pharma: The Spread of Multimodal
The pharmaceutical industry is shifting from single-mode to multimodal drug discovery, incorporating diverse therapeutic modalities like biologics, gene therapies, and small molecules, but this evolution presents significant challenges in integrating heterogeneous R&D data and technologies, necessitating advanced, compatible platforms to enable efficient collaboration and leverage AI-driven insights for faster, cost-effective drug development.
How Luma Lab Connect Automates Lab Data Acquisition Across 100+ Instruments
Dotmatics Luma Lab Connect, part of the Dotmatics Luma multimodal scientific R&D platform, automates and streamlines the acquisition, management, and preparation of complex, multimodal lab data from over 100 diverse instruments and sources, addressing challenges of data security, integrity, and usability to enhance research productivity and enable FAIR data practices within a unified, low-code SaaS environment.
Addressing Inefficient R&D Workflows
The blog discusses how legacy, fragmented R&D systems hinder innovation in complex, multi-domain scientific research by creating silos and inefficiencies, and presents Dotmatics’ unifying platform as a comprehensive solution that integrates diverse tools, data, and teams to enable smarter collaboration, governed data use, and AI-driven automation for faster, more rigorous innovation.
From Foundational to Aspirational: Dotmatics CEO on the Three Phases of R&D Digital Transformation
Dotmatics CEO outlines the accelerating digital transformation in life sciences R&D driven by exploding data volumes, emphasizing the shift towards AI and machine learning despite unique industry challenges such as lack of standardized interoperability and a fragmented ecosystem, which complicate progress toward a predictive, generative AI-enabled future in drug discovery.
Scripps News America Tonight
Phil Mounteney, VP of Science and Technology at Dotmatics, explains in Scripps News America Tonight how Dotmatics Luma uses AI to transform scientific research and pharmaceutical drug discovery by accelerating innovation, lowering costs, and shortening time-to-market for modern laboratories.